drugset / Trial / NCT00463775

Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence

NCT00463775

Phase 3 Withdrawn Elizabeth Ralevski
RandomizedFactorialTriple-blindTreatment

Summary

The objective of the present study is to evaluate the efficacy of topiramate (250mg/day) versus placebo in decreasing aggression and reducing alcohol consumption in patients with borderline personality disorder (BPD) and alcohol dependence (AD).

Timeline

Start
2007-03
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule 250 mg Oral